Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AMBI

AMBI (AMBI) Stock Price, News & Analysis

AMBI logo

About AMBI Stock (NASDAQ:AMBI)

Key Stats

Today's Range
$5.20
$5.89
50-Day Range
N/A
52-Week Range
N/A
Volume
3,364 shs
Average Volume
8,434 shs
Market Capitalization
$317.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Receive AMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBI and its competitors with MarketBeat's FREE daily newsletter.

AMBI Stock News Headlines

Ambipar Emergency Response Secures Financial Approval at 2024 AGM
Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed
Naya Ambi is the winner of 'The Clash' Season 6
See More Headlines

AMBI Stock Analysis - Frequently Asked Questions

AMBI (NASDAQ:AMBI) issued its earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.03. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.50 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that AMBI investors own include Alexion Pharmaceuticals (ALXN), Amarin (AMRN), Bristol-Myers Squibb (BMY), Broadcom (BRCM), Cytokinetics (CYTK), Delta Air Lines (DAL) and Fortress Biotech (FBIO).

Company Calendar

Last Earnings
5/06/2014
Today
12/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Sanitary services
Sub-Industry
N/A
Current Symbol
NASDAQ:AMBI
Fax
N/A
Employees
7,000
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$518.81 million
Cash Flow
$0.76 per share
Book Value
$4.90 per share

Miscellaneous

Free Float
46,561,000
Market Cap
$328.70 million
Optionable
Not Optionable
Beta
0.56
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AMBI) was last updated on 12/17/2024 by MarketBeat.com Staff
From Our Partners